The Tensin-3 Protein, Including its SH2 Domain, Is Phosphorylated by Src and Contributes to Tumorigenesis and Metastasis  by Qian, Xiaolan et al.
Cancer Cell
ArticleThe Tensin-3 Protein, Including its SH2 Domain,
Is Phosphorylated by Src and Contributes
to Tumorigenesis and Metastasis
Xiaolan Qian,1 Guorong Li,1 William C. Vass,1 Alex Papageorge,1 Renard C. Walker,2 Laura Asnaghi,1 Peter J. Steinbach,3
Giovanna Tosato,1 Kent Hunter,2 and Douglas R. Lowy1,*
1Laboratory of Cellular Oncology
2Laboratory of Cancer Biology and Genetics
Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
3Center for Molecular Modeling, Division of Computational Bioscience, Center for Information Technology, National Institutes of Health,
Bethesda, MD 20892, USA
*Correspondence: lowyd@mail.nih.gov
DOI 10.1016/j.ccr.2009.07.031
SUMMARY
In cell lines from advanced lung cancer, breast cancer, and melanoma, endogenous tensin-3 contributes
to cell migration, anchorage-independent growth, and tumorigenesis. Although SH2 domains have not
been reported previously to be phosphorylated, the tensin-3 SH2 domain is a physiologic substrate for
Src. Tyrosines in the SH2 domain contribute to the biological activity of tensin-3, and phosphorylation of
these tyrosines can regulate ligand binding. In a mouse breast cancer model, tensin-3 tyrosines are phos-
phorylated in a Src-associated manner in primary tumors, and experimental metastases induced by
tumor-derived cell lines depend on endogenous tensin-3. Thus, tensin-3 is implicated as an oncoprotein
regulated by Src and possessing an SH2 domain with a previously undescribedmechanism for the regulation
of ligand binding.INTRODUCTION
It is widely recognized that most cancers result from a multistep
genetic and epigenetic process that includes the inactivation of
tumor suppressor genes that inhibit growth and/or promote
apoptosis as well as the activation of oncogenes that promote
growth and/or inhibit apoptosis (Vogelstein and Kinzler, 2004).
Members of the DLC gene family (DLC1-3) of tumor suppressors
are growth inhibitory and proapoptotic and are inactivated in
a variety of tumors (Durkin et al., 2007). DLC proteins are found
in focal adhesions and can reduce the activity of Rho GTPases
via the Rho GTPase activating protein (Rho-GAP) domain
present in each DLC protein. Another antioncogenic activity of
DLC is its ability to bind the SH2 and PTB domains of tensin
proteins, which are found in focal adhesions (Liao et al., 2007;
Qian et al., 2007; Yam et al., 2006a).246 Cancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier IncMammals contain four tensin genes: tensin-1-3 and cten
(tensin 2 is also designated C1-ten; cten, for C-terminal tensin-
like protein, a truncated cten is also designated tensin-4) (Hafizi
et al., 2005; Lo, 2004). The proteins encoded by tensin-1-3 form
a link between the actin cytoskeleton and the intracellular portion
of some b-integrins, and are believed to participate in the regu-
lation of cell migration. Actin binding is mediated by sequences
in the N terminus of tensin-1-3, whereas integrin binding has
been localized to the PTB domain at their C terminus (Figure 1D).
The SH2 domain of tensin-1-3 lies just upstream of the PTB
domain, with unique sequences comprising the middle of each
protein. Cten, which is shorter than tensin-1-3, lacks the actin
binding sequences, but contains SH2 and PTB domains at its
C terminus, analogous to tensin-1-3.
SH2 domains are approximately 100 amino acids in length and
serve primarily as docking sites for the binding of signalingSIGNIFICANCE
The role of focal adhesion (FA) proteins in cancer is poorly understood. Here, tensin-3 is found to be an FA protein that
contributes to oncogenesis in human cancer cell lines and lines from a mouse cancer model. In addition, tyrosines in the
SH2 domain of tensin-3 contribute to its transforming activity. SH2 domains participate in tyrosine kinase signaling
pathways and bind ligands that are usually tyrosine phosphorylated, but we find that the tyrosines in the SH2 domain of
tensin-3 have in addition the previously undescribed property of being phosphorylated, by Src, an FA-associated non-
receptor tyrosine kinase activated in many cancers. This SH2 phosphorylation can facilitate the binding of SH2 ligands
such as p130Cas and FAK..
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Tensin-3 Contributes to OncogenesisFigure 1. siRNA for Tensin-3, But Not for Other Tensins, Specifically Inhibits Cell Proliferation, Anchorage-Independent Growth, and Cell
Migration
(A and B) NSCLC lines 1299 and A549: immunoblots of tensin-3 (tns3) and cten from whole-cell extracts (WCE) resulting from siRNA transfections; bioassays
carried out after treatment with the indicated siRNAs for growth in agar, cell migration (scale bars represent 100 mm), and MTT (shown in graph as mean ±
SD). No detectable tns1 by immunoblot in H1299 cells (data not shown).
(C) Cooperation of tns3 with SrcY527F in cell transformation and migration. Focus formation induced by SrcY527F was reduced as shown by mouse tns3 siRNA
transfection in NIH 3T3 cells (left panels, graphed as mean and standard deviation [± SD]); cell migration was increased by overexpression of GFP-tns3 in 3T3Src
cells, as shown by transwell migration assay (right panels, scale bars represent 100 mm).
(D) Schematic representation of the four tensin proteins.molecules involved in tyrosine kinase-dependent pathways (Liu
et al., 2006; Machida and Mayer, 2005). Most SH2 domains
have several physiologic ligands, whose tyrosine phosphoryla-
tion is usually required for efficient binding to their cognate
SH2 motifs (Huang et al., 2008). The tensin SH2 domain can
form a complex with several tyrosine phosphorylated proteins,
including p130Cas and FAK, which are pro-oncogenic factors
(Cui et al., 2004; Defilippi et al., 2006; Mitra and Schlaepfer,
2006). However, unphosphorylated DLC can efficiently bind
the tensin SH2 domain (Liao et al., 2007), and DLC can compete
with other ligands for occupying the SH2 domain of tensin and
with b-integrin for binding the PTB domain (Qian et al., 2007).
The ability of the tensin SH2 domain to bind pro-oncogenic
ligands raises the possibility that under conditions permissive
for such binding, a tensin protein might contribute to the onco-
genic phenotype. However, as is true for most focal adhesion
proteins (Lindberg et al., 2008), a role for tensin in tumors has
not been clearly identified. For example, overexpression ofCtensin-1 has been reported to promote cell migration (Chen
et al., 2002), a feature of many cancer cells, but tensin-1 may
be silenced in human breast and prostate cancer cell lines
(Chen et al., 2000). Although full-length tensin-2 can inhibit cell
migration and growth, and promote apoptosis (Hafizi et al.,
2005; Yam et al., 2006a), overexpression of an alternatively
spliced formof tensin-2 canpromote cell growth and transforma-
tion (Yam et al., 2006b), with both forms often being coregulated
in tumor cell lines (Yamet al., 2006a; Yamet al., 2006b). Ctenwas
reported downregulated in most prostate tumor cell lines (Lo and
Lo, 2002), and its overexpression in a breast cancer line had no
phenotype (Lo and Lo, 2005). Other studies describe cten as
contributing to EGF-dependent cell migration in MCF10A cells,
a nontransformed human breast cell line, and that it was
expressed in breast cancer (Katz et al., 2007).
For this analysis of tensin in cancer, we focused on the role of
endogenous tensin protein in cell lines derived from advanced
human non-small cell lung cancer (NSCLC), breast cancer, andancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier Inc. 247
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Tensin-3 Contributes to Oncogenesismelanoma, because DLC1 has been reported to be inactivated
in a majority of NSCLC and about one-half of breast cancers,
whereas melanoma represents a common non-epithelial tumor
(Durkin et al., 2007; Healy et al., 2008; Plaumann et al., 2003;
Yuan et al., 2004; Yuan et al., 2003). The contribution of the
tensin SH2 domain to this process was also analyzed.
RESULTS
Tensin-3 Contributes to Cell Migration and Growth
of Cancer Cell Lines
We first explored whether any tensin gene might be required for
biological properties associated with oncogenesis in two widely
studied NSCLC lines, H1299 and A549, by treating each line with
interfering RNAs (siRNA) specific for each of the four tensins
(Figures 1A and 1B; see Figures S1A and S1C available online).
Preliminary analysis indicated that H1299 expresses each tensin
gene except tensin-1, whereas A549 expresses all four tensins.
siRNA treatment led to a > 80% reduction in the endogenous
level of the relevant RNA or protein in both lines (Figures 1,
S1A, and S1C). The knockdown of tensin-3, but not the other
tensin proteins, resulted in a marked reduction of anchorage-
independent growth in soft agar, cell migration by transwell or
wound-healing assays, and monolayer growth by MTT assay.
Similar results were also seen with a third NSCLC line, H358
(data not shown). The inhibition of growth and migration was
seen whether tensin-3 was reduced by a mixture of four specific
siRNAs or the single siRNA (09) determined to be the most
efficient in its reduction (Figures 1A, 1B, and S1C). Possible
off-target effects of the siRNAs were ruled out by the ability of
a GFP-tensin-3 expression plasmid to largely overcome the
inhibitory effects of the tensin-3 siRNA mixture on migration
and anchorage-independent growth, and the lack of effect of
the (09) siRNA on the migration rate of a mouse cell line,
Met-1, whose migration rate was inhibited by an siRNA directed
against mouse tensin-3 (Figure S2).
We also tested three metastatic melanoma cell lines, mel
553B, mel 1088, and mel 568, in soft agar and cell migration
assays for their dependence on tensin-1 or tensin-3 (Figure S1D,
data shown for 553B and 1088). As with the NSCLC lines, siRNA-
mediated reduction of tensin-3 in the melanoma lines strongly
inhibited their growth in agar and cell migration, in contrast to
the limited effects resulting from reduction of tensin-1. A more
limited analysis was carried out for a breast cancer line known
to express high levels of tensin-3 (Cui et al., 2004), MDA-MB-
468, by comparing the consequences of tensin-1 or tensin-3
siRNA in a wound-healing assay, because this line migrates
rapidly but does not grow efficiently in soft agar. Reduction of
tensin-3 slowed the migration of cells into the wound, whereas
tensin-1 siRNA had a negligible effect (Figure S1B). Thus, ten-
sin-3 contributes to the biological activities of each line.
Tensin-3 Expression Influences Transformation
by Activated Src
The above results were extended to a system in which cells were
experimentally transformed by the non-receptor tyrosine kinase,
Src. First, NIH 3T3 cells were treated with mouse tensin-3 siRNA
and acutely transformed with a constitutively active form of Src
(Src-Y527F). The tensin-3 siRNA induced a 5-fold reduction in248 Cancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier Incthe number of Src-induced foci compared with the Risc-free
control (Figure 1C, left panels). Second, full-length tensin-3
was overexpressed in NIH 3T3 cells that had been transformed
with Src-Y527F (3T3Src cells), which increased the rate of cell
migration in the transwell assay (Figure 1C, right panels). These
data indicate that tensin-3 expression influences Src-induced
transformation and migration of NIH 3T3 cells.
Tensin-3 Is a Src Substrate
Given the biological importance of tensin-3, we focused on it in
subsequent analyses. When tensin-3 and its tyrosine phosphor-
ylation were examined in a panel of untransformed, NSCLC,
breast cancer, and melanoma lines grown in 10% fetal calf
serum, the level of tensin-3 in some untransformed lines (e.g.,
1634 and WI38 fibroblasts) was as high as in tumor lines, but
the protein tended to be less tyrosine phosphorylated than in
the tumor lines (Figure 2A). Two apparent exceptions to the
high phosphotyrosine were the MCF-7 breast cancer line and
the H1299 NSCLC line. MCF-7 has relatively low oncogenicity
(Bergamo et al., 2008), which might correlate with the low tyro-
sine phosphorylation of its tensin-3. The level of tensin-3 was
similar in the H1299 line and the HBEC (human bronchial epithe-
lial cell) line, an immortalized but nontumorigenic lung epithelial
line widely used as a normal control for lung cancer lines, but
the degree of tensin-3 tyrosine phosphorylation was greater in
H1299 than in HBEC.
Cell transformation by Src can induce tyrosine phosphoryla-
tion of chick tensin (Davis et al., 1991). Here, we found a reason-
able correlation between the level of Src kinase activity and
tensin-3 phosphotyrosine (Figure 2A). Tensin-3 phosphorylation
depended upon Src as siRNA-induced knock down of Src in two
NSCLC lines, H358 and A549, resulted in almost complete loss
tensin-3 phosphotyrosine, whereas siRNA knock down of
E-cadherin, a specificity control, did not (Figure 2B). Treatment of
these two lines and two other NSCLC lines, H1299 and H727,
with the Src family kinase inhibitor PP2 also abolished the
majority of tensin-3 phosphorylation (Figure 2D). Tensin-3 phos-
photyrosine was constitutive in the NSCLC lines and did not
depend upon EGFR, because neither serum deprivation nor
treatment with the EGFR inhibitor PD 98059 affected the level
of tensin-3 phosphotyrosine (Figures 2D and S3C). In two breast
cancer lines that express high levels of EGFR,MDA-MB-468 and
SKBR3, EGF could increase tensin-3 phosphorylation, but,
consistent with previous data in MDA-MB-468 (Cui et al.,
2004), even this increase could be prevented by PP2 (Figure 2C).
In untransformed human fibroblasts, PDGF induced tyrosine
phosphorylation of tensin-3 that was inhibited by PP2 and by
the PDGFR inhibitor PI (Figures 2E, left panel, and S3A).
However, EGF did not induce tensin-3 phosphorylation in the
fibroblasts or increase its phosphorylation in the H727 NSCLC
line as well as several other lines (Figures 2C, 2E, S3A, and
data not shown). Thus, physiologic levels of PDGFR can induce
tensin-3 phosphorylation in response to PDGF, whereas its
induction by EGF might require overexpression of EGFR.
Given the dependence of tensin-3 phosphorylation on Src, we
tested whether tensin-3 is a direct substrate for Src. Indeed,
addition of recombinant active Src to anti-tensin-3 immune
complexes from serum-depleted 1634 cell extracts resulted in
phosphorylation of tensin-3 that was prevented by PP2.
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Tensin-3 Contributes to OncogenesisFigure 2. Hyperphosphorylation of Tensin-3 in Cancer Cell Lines Is Directly Regulated by Constitutive Src Kinase Activity
(A) Hyperphosphorylation of tns3 is correlated with Src activity in cancer cell lines. Immunoblots (IB) showing relative levels of tns3 phosphotyrosine, total tns3,
Src kinase activity, and b-actin loading control. Tns3 protein and its tyrosine phosphorylation (pY) status were determined by analyzing the anti-tns3 immuno-
precipitates (IP) with anti-tns3 or anti-phosphotyrosine (PY) antibody (Ab), respectively. Src kinase activity was determined by in vitro kinase assay.
(B) Src siRNA reduces tns3 phosphorylation. pY tns3 and protein level (top panels) were examined by immunoblots 4 days after transfection of Src or E-cadherin
control siRNA (bottom panels).
(C) EGF stimulation of tns3 phosphorylation in breast (MDA-MB-468 and SKBR3) and NSCLC (H727) lines. Cell extracts were analyzed for pY tns3 after acute
treatment with EGF (100 ng/ml) for 15 min, with or without the indicated inhibitor. PD, PD 98059 EGFR inhibitor.
(D) Tns3 phosphorylation in NSCLC is sensitive to PP2 Src inhibitor, but not to serum depletion. Cells were cultured with or without 10%FBS, with or without PP2,
followed by IP and IB analysis of pY tns3 (upper panels) and tns3 protein (lower panels).
(E) PDGF induces tns3 phosphorylation in human fibroblasts (left panels); Src, but not EGFR, directly phosphorylates tns3 in vitro (right panel). Left panels: Serum-
depleted human fibroblasts (1634) were treated with or without the indicated kinase inhibitors followed by PDGF or EGF stimulation, and pY tns3 was detected in
anti-PY blots after anti-tns3 Ab IP of cell extracts. Right panel: Anti-tns3 immunocomplexes from 1634 cells were subjected to an in vitro kinase assay in the
presence of the indicated added active recombinant kinase with or without the indicated kinase inhibitor. The autoradiogram shows pY tns3 and the added
kinases.(Figure 2E, right panel). Adding active PDGFR to the immunopre-
cipitates also led to tensin-3 phosphorylation, although less than
with Src, and this phosphorylation was inhibited by PI. Similar
results were also obtained when active Src was added to
tensin-3 immunoprecipitates from two NSCLC lines and the
MDA-MB-468 breast cancer line or H1299 cells expressing
GFP-tensin-3 (Figure S3D). By contrast, addition of active
EGFR to the immunoprecipitates did not result in phosphoryla-
tion of tensin-3, or Src, although EGFRwas auto-phosphorylated
as expected (Figures 2E and S3D). We conclude tensin-3 is
a direct substrate for Src, but not for EGFR.
Interaction of Tensin-3 with p130Cas and Sam68
Is Src Dependent
Using endogenous vinculin as a marker of focal adhesions, we
confirmed the localization of endogenous tensin-3 to focal adhe-
sions and its partial colocalization with FAK and p130Cas in the
A549NSCLC line (Figure 3A) (Cui et al., 2004). Although p130Cas
was present diffusely in the cytoplasm, phosphorylated p130CasC(pp130Cas), recognized by an antibody to pY410, preferentially
colocalized with tensin-3 in focal adhesions (Figures 3B and
S3E). p130Cas is a Src substrate, and treatment with PP2
decreased the amount of p130Cas recognized by the pY410
antibody or colocalized with transfected GFP-tensin-3 (Fig-
ure 3B). Consistent with these immunocytological observations,
complex formation between endogenous p130Cas and endoge-
nous tensin-3 in two NSCLC lines was reduced by PP2 treatment
(Figure 3C). Another Src substrate, Sam68, which we confirmed
is present in the cytoplasm and nucleus of H727 NSCLC cells
(data not shown), also forms a PP2-sensitive endogenous
complex with tensin-3 (Figure 3D). These experiments strongly
suggest the interaction of tensin-3 with p130Cas and Sam68 is
dependent on Src activity.
The Tensin-3 SH2 Domain Is Phosphorylated by Src
To identify tyrosines in tensin-3 that might be substrates for
phosphorylation, we expressed several tensin-3 fragments,
including 1-440, 416-931, and 1136-1445, which encodes theancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier Inc. 249
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Tensin-3 Contributes to Oncogenesislinked SH2 and PTB domains (SH2-PTB). Preliminary experi-
ments indicated each of these fragments was tyrosine phos-
phorylated when transfected into 3T3Src cells (data not shown).
The phosphotyrosine residues in the 1-440 and 416-931 frag-
ments have not been mapped. However, at least some of the
phosphorylated tyrosines in SH2-PTB mapped to the SH2
domain, because antiphosphotyrosine immunoblotting of gluta-
thione pull downs of a GST fusion protein encoding the tensin-3
SH2 domain alone in HEK293T (293T) cells identified the SH2
domain, and Src (Figure 4A, left panel). The chick tensin SH2
domain behaved similarly, whereas SAP was not detectably
phosphorylated, although its SH2 domain contains seven
tyrosines.
Because tyrosine phosphorylation of an SH2 domain does not
seem to have been characterized previously, this aspect was
analyzed further. The tensin-3 SH2 domain has three tyrosines:
Y1173, Y1206, and Y1256 (Figure 4A, diagram). To confirm
that they account for the apparent tyrosine phosphorylation in
the SH2 domain, all three tyrosines were mutated to phenylala-
nine (the 3F mutant) and expressed as a GST fusion protein.
Pull down of the SH2 3F protein indicated it was not tyrosine
phosphorylated and was not associated with Src (Figure 4A,
left panel). Analogous results were obtained in 293T, MDA-MB-
468, and 3T3Src cells when pull downs of the wild-type and 3F
mutant SH2 domains were reacted with endogenous kinase
included in the pull-down pellets (Figures 4A, right panel, lanes
1–4, 4B, and 4C) or following addition of recombinant active
Figure 3. Tensin-3 Associateswith Endoge-
nous Focal Adhesion Proteins in NSCLC
Cell Lines
(A) Endogenous tns3 in A549 cells partially coloc-
alizes with endogenous vinculin (a marker of focal
adhesions), p130Cas, and FAK. The confocal
images are representative of more than 50 cells
observed. The frequency of each colocalization
was > 90%. Scale bars represent 10 mm.
(B) Src activity is required for efficient colocaliza-
tion of tns3 with pp130Cas. Treatment with PP2
reduced the level of p130Cas-pY410 and the
colocalization between pp130Cas and GFP-tns3.
The images are representative of more than 70%
of the cells.
(C) Endogenous tns3 and p130Cas-pY410 form
a complex in NSCLC lines that is reduced by
PP2, as determined p130Cas-pY410 IP (upper
panels) or tns3 IP (lower panels) and immunoblot-
ting with the reciprocal Ab.
(D) Complex formation between tns3 and Sam68
in H727 NSCLC cell line. Cells were treated with
or without PP2, and extracts were immunoprecip-
itated with anti-Sam68 Ab or control IgG followed
by IB with tns3 (top) or Sam68 antibodies.
Src to the pellets (Figure 4A right panel,
lanes 5–8). Phosphorylation of the SH2
domain could be blocked by herbimycin
A (HA), which is often used to inhibit tyro-
sine kinase activity. When the 3F muta-
tions were engineered into SH2-PTB
and expressed in 3T3Src cells, there was
no detectable tyrosine phosphorylation (Figure 4C), indicating
the phosphorylation in SH2-PTB depended on the tyrosines in
the SH2 domain.
The Tyrosines in the SH2 Domain Are Required
for Complex Formation with Several Proteins
The SH2 tyrosine phosphorylation raised the possibility that
binding of at least some ligands for the tensin-3 SH2 domain
might depend upon one or more of the tyrosines in the domain.
To determine the relative importance of the tyrosines, each
was mutated to phenylalanine as single (Y1173F, Y1206F,
and Y1256F) and double mutants (Y1173F/Y1206F [2F] and
Y1206F/Y1256F [2F’]), in addition to the SH2 3F triplemutant, en-
gineered as GST fusion proteins, and compared with wild-type
GST-SH2 (SH2 WT). The GST pull down confirmed that SH2
WT bound to pp130Cas (Figures 4B and 4D), Src (Figures 4B
and 4C), FAK (Figure 4D, right panel), and Sam68 (Figure S4A),
and in addition determined that SH2 formed a complex with
endogenous integrin-linked kinase (ILK) (Figure 4D) and DLC1
(Figure S4B). Except for FAK and Sam68, the ligands did not
bind SAP, indicative of tensin-3 SH2 complex specificity. When
the tensin-3 SH2 WT was compared with SH2 3F, the binding
of FAK, p130Cas, Src, and Sam68 was found to depend on the
three tyrosines, whereas that of DLC1 and ILK was substantially
less tyrosine dependent. Y1173 and Y1206 appeared to bemore
important thanY1256 for p130Cas, FAK, andSrcbinding (Figures
4B and 4D).250 Cancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier Inc.
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Tensin-3 Contributes to OncogenesisFigure 4. Tyrosine Phosphorylation of Tensin-3 SH2 Domain In Vivo and In Vitro, and Binding of SH2 Ligands
(A–C) The SH2WT, but not the SH2 3F mutant or SAP, is tyrosine phosphorylated in vivo and in vitro. A schematic representation of the tns3 SH2 domain with its
three tyrosine residues and substitution mutants is shown at the bottom of A. GST and GST-SH2 constructs were transiently expressed, and treated with or
without HA, followed by pull-down assay with glutathione-Sepharose 4B (PD Gluta). The anti-pY IB and GST loading control are shown (A, left panels). The
pull-down pellets were subject to an in vitro kinase assay incorporating g-32P-ATP either by addition of active Src kinase (A, right panel, lanes 5–8) or by endog-
enous Src family kinases in the pull-down pellet (A–C). A small aliquot of the samples was analyzed by anti-PY IB (C) or anti-GST IB to show the expression of each
construct and loading controls (B and C).
(D) Phenylalanine substitution mutations in the SH2 domain affect the binding of some, but not all, endogenous ligands. After PD Gluta of the transfected
GST-SH2 constructs, the endogenous ligands were detected in immunoblots with specific antibodies as indicated. The transfected GST and GST-SH2 fusion
proteins are also shown.The Tyrosine-Phosphorylated SH2 Domain Binds Src,
FAK, p130Cas, and Other Ligands More Efficiently
Than Does the Nonphosphorylated SH2 Domain
The above results indicate that the tyrosines in the SH2 domain
serve a critical role for the binding of some ligands. However,
they do not address whether the tyrosine phosphorylation of
the SH2 domain contributes to ligand binding. To explore this
possibility, we prepared purified GST-SH2 fusion proteins,
from human tensin-3 and chick tensin that were tyrosine phos-
phorylated or not (Figures 5A and 5B), and the relative ability of
the preparations to bind ligand was assessed in two different
assays. In one, the purified phosphorylated or nonphosphory-
lated SH2 domains were added to extracts from 3T3Src cells
expressing transfected full-length p130Cas, and pull-down
assays identified the bound ligands (Figure 5C). This analysisCindicated that both p130Cas and Src bound the tyrosine
phosphorylated SH2 domains more efficiently than did the non-
phosphorylated SH2 domains or the 2F mutant. In the other
assay, far-western blotting was carried out, with the purified
phosphorylated and nonphosphorylated SH2 domain ‘‘bait’’
being incubated with cell extract ‘‘prey’’ that had previously
been immunoprecipitated with anti-phospho-FAK antibodies or
anti-p130Cas antibodies and then subjected to gel electropho-
resis, membrane transfer, and renaturation. The anti-FAK prep-
aration, which was isolated from H358 NSCLC cells, showed
the tyrosine-phosphorylated tensin-3 SH2 domain bound more
efficiently to the immobilized endogenous FAK (Figure 5D), as
was also true for phosphorylated chick tensin SH2 and p130Cas
(Figure 5E, top panels). A far-western blot of ‘‘prey’’ from 3T3Src
cell extracts that had been immunoprecipitated with anancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier Inc. 251
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Tensin-3 Contributes to OncogenesisFigure 5. Tyrosine Phosphorylation of SH2 Domain Facilitates the Binding of FAK, Src, and p130Cas
(A and B) Purification of tyrosine phosphorylated and nonphosphorylated bait tensin-3 SH2. GST, GST-SH2 WT, and GST-SH2 2F mutant constructs, or chick
tensin (CK) SH2were transiently expressed in 3T3Src cells (A, left panel) or 293T cells (A, right panel, and B), and treatedwith or without HA, followed by extraction
and PD Gluta assay (A, left panel only). The unpurified and purified bait proteins were analyzed by anti-pY IB and anti-GST IB as loading controls (A, right panel,
and B).
(C) Transfected p130Cas and endogenous Src in extracts from 3T3Src cells preferentially bind the purified phosphorylated SH2 bait proteins shown in (B). After
pull down with glutathione beads, the binding of p130Cas and Src from the cell extracts was analyzed by IB. The pY SH2 protein added to the cell extracts is also
detected in the anti-PY blot.
(D) Far-western blotting of purified bait tns3 SH2 to prey protein FAK. Endogenous FAK in H358 cells was isolated by IP with anti-FAK PY397 Ab. After gel
electrophoresis, membrane transfer, and renaturation, the FAK-containing membrane underwent far-western blotting with the purified SH2 baits from A followed
by anti-GST IB (upper panels).
(E) Far-western blotting of purified bait SH2 to prey proteins p130Cas, Src, and other ligands. Top panels: p130Cas immunoprecipitates from p130Cas
transfected 293T cells were subject to in vitro Src Kinase Reaction (SKR) with active recombinant Src kinase and then processed and analyzed as for FAK in
D, except that the bait SH2 proteins were from B. Bottom panels: pY immunoprecipitates from Src3T3 cells were processed and analyzed as in the upper panels.anti-phosphotyrosine antibody indicated that, in addition to Src
protein, other tyrosine phosphorylated proteins bind the phos-
phorylated tensin-3 SH2 domain more efficiently than does the
nonphosphorylated or 2Fmutant SH2 domain (Figure 5E, bottom
panels).
The Tyrosines in the SH2 Domain Contribute
to the Biological Activity of Tensin-3
To explore whether the tensin-3 dependence in vitro biological
activities (Figure 1) also applied to tumor formation in vivo, the
H1299 NSCLC line was treated with siRNA to knock down
tensin-3 or cten, and its ability to form tumors as xenografts in
NOD/SCID mice examined. The knock down of tensin-3, but
not cten, significantly suppressed tumor formation, in addition
to growth in soft agar and cell migration (Figure 6A).
In Drosophila, the SH2-PTB domains of D. tensin can act as
a dominant negative mutant (Torgler et al., 2004). Similarly, we
found that tensin-3 GST-SH2-PTB WT, but not the 3F mutant252 Cancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier Inversion, can act as a dominant negative mutant in mammalian
cells, because stable H1299 WT transfectants had reduced
numbers of migrated cells compared with the 3F transfectants
(Figure 6B, two left panels). GST-SH2WT also displayed a domi-
nant negative phenotype in a colony growth assay of H358
cells, which was attenuated in the 2F and 3F mutant versions
(Figure 6B, two right panels).
In addition, a transfectant overexpressing GFP-tensin-3 WT
in H1299 cells, which express modest levels of endogenous
tensin-3 (Figure 2A), was more active by transwell cell migration
and anchorage-independent growth in agar, and formed larger
tumors in vivo than the control transfectant (Figure 6C). By
contrast, a 2F clone that expressed GFP-tensin-3 protein in
which the first two tyrosines of the SH2 domain had been
mutated to phenylalanine was less active than the wild-type.
Thus, tensin-3 can increase the oncogenic properties of
H1299, and tyrosines in the SH2 domain contribute to this
activity.c.
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Tensin-3 Contributes to OncogenesisFigure 6. Tyrosines in Tensin-3 SH2 Domain Influence the In Vitro and In Vivo Biological Activity of Tensin-3 in H1299 Cells
(A) tns3 siRNA inhibits the growth of H1299 tumor xenografts in NOD/SCID mice. NSCLC H1299 cells transfected with the indicated siRNA, and injected subcu-
taneously into NOD/SCIDmice. Tumors were weighed 4weeks later. The results are expressed asmeans ± SD (n = 8). Statistical significancewas analyzed by the
nonparametric Mann Whitney t test. At the time the cells were injected, the knock down of tns3 protein expression was confirmed by IB, and some cells were
assayed by transwell migration and soft agar colony growth as shown. Scale bars represent 100 mm.
(B) Dominant negative effect of stable clones expressing the tns3 SH2-PTB and SH2 domains and attenuation by phenylalanine mutation of the SH2 tyrosines.
H1299-8, a fast-growing subclone of H1299 cells, stably expressed GST and GST-SH2-PTB (wt or 3F mutant) as shown by IB (left outer panel). Cells were
analyzed by transwell migration assay (left inner panel, Scale bars: 100 mm). H358 cells stably expressed GST-SH2-PTB (wt, 2F, or 3F mutants) as shown by
IB (right inner panel). Cells were analyzed by G418 resistant colony growth assay (right outer panel).
(C) Overexpression of wild-type GFP-tns3 in H1299 cells enhanced biological activity in vitro and in vivo, and the 2F mutant was less active. H1299-1, a slow
growing subclone of H1299 cells, stably expressed GFP-tagged full-length wt or 2F mutant tns3 as shown by IB (left outer panel). The tumor xenografts in
NOD/SCID mice induced by these cells were plotted as means ± SD (n = 9), and p values were calculated as for A (right outer panel). At the time the cells
were injected, some cells were analyzed by transwell migration (left inner panel) and soft agar colony growth (right inner panel). Scale bars represent 100 mm.
Data shown are representative of three independent experiments.Tensin-3 Contributes to Tumorigenesis and Metastasis
in Cell Lines Derived from aMouse Breast CancerModel
The human cell line data suggested that an experimental tumor
model in which Src was activated might have increased tyrosine
phosphorylation of tensin-3. To explore this possibility, we
examined tensin-3 tyrosine phosphorylation in primary tumors
from a transgenic mouse breast cancer model in which the
MMTV promoter drives expression of the polyoma middle T
antigen (PyMT), which activates endogenous Src (Guy et al.,
1994). In tumors from transgenic FVB mice, we confirmed that
Src was activated, and found that tensin-3 was expressed and
tyrosine phosphorylated in extracts from 5/5 primary tumors,
whereas its level of expression and tyrosine phosphorylation
were almost undetectable in extracts of normal FVB mammary
glands (Figures 7A and 7B). In the Met-1 and PyMT cell lines
derived from PyMT mammary tumors that arose in FVB mice,
tensin-3 was tyrosine phosphorylated to a degree similar to
that seen in the MDA-MB-468 human breast cancer line; thisCphosphorylation could be blocked by treating the cells with the
Src inhibitor PP2 (Figure 7C). Similar results were seen with the
Pei-1 line, which is derived from an FVB mammary tumor
induced by c-Myc/VEGF transgenes.
siRNA treatment determined that tensin-3 is biologically
relevant in the Met-1 and PyMT lines, because anchorage-inde-
pendent growth in soft agar, orthotopic tumor formation under
the mouse breast fat pad, and lung tumor nodules following tail
vein inoculation were inhibited in both lines, compared with the
Risc-free treated control cells (Figures 7D, 7E, and 7F). Met-1
cells were inhibited to a greater degree than the PyMT cells.
Thus, tensin-3 in these lines contributes to in situ tumor forma-
tion and metastasis.
DISCUSSION
The current report makes two unexpected observations with
implications for cancer and signaling via SH2 domains. One isancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier Inc. 253
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Tensin-3 Contributes to OncogenesisFigure 7. Analysis of Mouse Tensin-3 In Vivo
(A) Src kinase is activated and tns3 expression is increased in primary breast cancers induced by polyoma MT in transgenic FVB mice, compared with normal
breast tissue. The pY proteins, in vitro Src kinase activity, and tns3 expression are shown. The b-actin IB serves as a loading control.
(B) Tyrosine phosphorylation of mouse tns3 in vivo. Mouse tns3 from normal and tumor tissue extracts were immunoprecipitated by tns3 Ab followed by anti-PY
IB. The H1299 line stably expressing GFP-tns3 served as a positive control.
(C) Mouse FBV-derived tumor cell lines were treated with or without PP2 and analyzed for pY tns3 as in (B). The MDA-MB-468 line served as a positive control.
(D–G) tns3 siRNA attenuates the biological activity of the Met-1 and PyMT cell lines in vitro and in vivo. Mouse tns3 siRNA was transfected into Met-1 and PyMT
cells, and the siRNA knock-down efficiency was confirmed by IB (D). Forty-eight to seventy-two hours after transfection, cells were prepared for soft agar colony
growth (scale bar represents 100 mm in D), orthotopic tumor growth under the breast fat pad of FVBmice (E), and tail vein injections of FVB (F andG). The results of
orthotopic tumor weights are expressed asmeans ± SD (E). A representative section of H&E-stained lung frommice injected by tail vein is shown (F). Lungmetas-
tases on stained slideswere countedmanually under amicroscope, andmean number per section ± SD is plotted (G). Statistical significance was analyzed by the
nonparametric Mann Whitney t test.that endogenous tensin-3 makes a major contribution to main-
taining the oncogenic growth properties of cell lines from
advanced human NSCLC, breast cancer, and melanoma, and
a widely used mouse model of breast cancer.
The other observation is that tyrosines in the tensin-3 SH2
domain can be phosphorylated both in vivo and in vitro and
can bind ligands more efficiently when the SH2 tyrosines are
phosphorylated. Although tyrosine phosphorylation of SH2
ligands is usually required for efficient binding to their cognate
SH2 motif, the possibility that phosphorylation of tyrosines in
the SH2 domain itself might contribute to this process has not
been examined previously.
Here, we have extensively documented the role of tensin-3
in maintaining the transformed properties of cell lines from
advanced cancers. However, a positive role for tensin-3 might
be variable in cells from less advanced cancers, and, given the
various routes by which cells may become malignant, there
might be advanced cancers from other tumor types, or even254 Cancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier Incfrom those types examined here, in which tensin-3may not serve
this role. For example, Martuszewska et al. (2009) reported that
the levels of tensin-3 in renal cancer are about one-half those in
the normal kidney, but did not examine the biological role of
tensin-3 in renal cancer. In our studies, although tensin-3 levels
in the H1299 NSCLC line were lower than in other NSCLC lines,
tensin-3 still made an important contribution to the oncogenic
properties of this line. Martuszewska et al. (2009) also found
that siRNA-mediated knock down of tensin-3 in a melanoma
cell line (the only cancer cell line tested and the only bioassay
assessed) resulted in about a 15% increase in cell migration
compared with cells treated with the control siRNA. In contrast
to the metastatic melanoma lines studied here, this line was
isolated from a primary melanoma, and is reported to be less
invasive than metastasis-derived lines and have distinct
signaling properties (Smalley et al., 2006).
Our analyses strongly suggest that Src is the major tyrosine
kinase responsible for the observed phosphorylation of.
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Tensin-3 Contributes to OncogenesisFigure 8. Model of Tensin-3 SH2 Domain, and Summary of Tensin-3 Regulators and Effectors
(A) Top: Alignment of tns3 SH2-domain sequences, residues 1171-1268, with Lck SH2 domain sequences, residues 126-211, used in modeling the SH2 domain
of tns3. The three tns3 tyrosines aremarked with an asterisk. Bottom: Homologymodel of tns3 SH2 domain with the pentapeptide DpYDYV bound, built using the
SH2 domain of Lck with peptide bound as template, as described in Supplemental Data. The bound peptide is shown in a ball-and-stick representation, and the
three tyrosine residues of the SH2 domain are shown as space-filling. The main chain of the modeled domain is colored by its identity to the template: yellow
where identical and light blue where different. Although the overall identity is not high (23%), the residues extending inward from the two helices are conserved.
(B) Tns3 activators and effectors, as determined by the data in this report. It highlights the importance of Src in phosphorylating tns3, including the SH2 domain,
the two classes of SH2 ligands, and the biological activities inhibited by tns3 siRNA and dominant negative tns3.full-length tensin-3 and its SH2 domain, although this function
may also be carried out by other Src family kinases (Parsons
and Parsons, 2004) as well as other tyrosine kinases, such as
FAK, which is a ligand for the tensin-3 SH2 domain (Manning
et al., 2002). Tyrosine phosphorylation in tensin-3, including its
SH2 domain, was constitutive in the tumor cell lines, and could
be reduced by the siRNA-dependent knock down of Src or
pharmacologic inhibition of Src activity.
The ability of the tyrosine phosphorylated tensin-3 SH2
domain to bind ligand more efficiently represents a potentially
important level of SH2 domain regulation, which may be a
dynamic process antagonized by tyrosine phosphatases.
Although tyrosine phosphorylation of the tensin-3 SH2 domain
and its ligands may frequently occur together, there could be
instances of reduced binding of tyrosine phosphorylated
ligands because the SH2 domain tyrosines are under-phos-
phorylated.
The tensin-3 SH2 domain has three tyrosines: residues 1173,
1206, and 1256; each appear to be phosphorylated in vivo. A
homology model of the tensin-3 SH2 domain is shown in Fig-
ure 8A, based on the crystal structure of the SH2 domain of
the Src family kinase Lck and a bound pentapeptide (Nasertorabi
et al., 2006). It suggests that Y1173 and Y1206, the two tyrosines
identified here as being most important for ligand binding, are
positioned close to each other, near the assumed binding site of
the pentapeptide, and somewhat distant from Y1256. The three
SH2 tyrosines in tensin-3 appear to be retained in tensin-2,
whereas the amino acid residue corresponding to Y1256 in
tensin-3 is N in tensin-1, and those corresponding to Y1173
and Y1206 in tensin-3 are both F in cten (Cui et al., 2004). SrcCbinding per se might not be sufficient for tyrosine phosphoryla-
tion of an SH2 domain; Src bound the SAP SH2 domain in
Src3T3 cells less efficiently than to the tensin-3 SH2 domain,
and there was no detectable phosphorylation of SAP, although
two of the seven tyrosines in the SAP SH2 domain are apparently
homologous to Y1173 and Y1206 of the tensin-3 SH2 domain.
Src substrates are heterogeneous (http://phospho.elm.eu.org/),
which makes it difficult to pinpoint the key surrounding amino
acids that may account for the observed difference in phosphor-
ylation. A tyrosine residue in the N-terminal SH2 domain of the
SHP-2 tyrosine phosphatase was recently reported to be phos-
phorylated indirectly by the Abl kinase (Mitra et al., 2008). It is not
homologous to any of the tensin SH2 tyrosines, and its possible
role in SH2 binding was not examined.
As indicated in Figure 8B, which summarizes many of the
findings reported here, we identified two classes of ligands
that formed a complex with the tensin-3 SH2 domain: one,
represented by DLC1 and ILK, whose binding was relatively
insensitive to mutation of the SH2 tyrosines, whereas the other,
represented by Src, p130Cas, FAK, and Sam68, was dependent
on the SH2 tyrosines. Members of the latter class bound more
efficiently in vitro to the tyrosine phosphorylated SH2 domain
and in vivo displayed reductions in binding to mutants in which
one or more of the SH2 tyrosines had been mutated to phenylal-
anine. The evidence strongly suggests that binding of the latter
class contributes to the pro-oncogenic activity of tensin-3,
because the wild-type SH2 domain behaves as a dominant
inhibitory mutant for wild-type tensin-3, whereas the 3F SH2
domain does not, and expression of wild-type tensin-3 can
induce anchorage-independent growth of cultured cells andancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier Inc. 255
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is less active in these assays.
The biological activity of tensin-3 is likely to depend to some
degree on sequences that lie outside the SH2 domain, but
consideration of only the SH2 domain and whether it binds
growth inhibitory or growth promoting ligands suggests that it
could affect tumorigenesis negatively or positively. DLC genes
are growth inhibitory and encode physiologic ligands that can
bind tensin SH2 domains whether or not the DLC protein is
phosphorylated (Liao et al., 2007) and independent of the SH2
tyrosines, as found here. Furthermore, wild-type DLC1 can
compete with other ligands for binding tensin SH2 domains
(and with b-integrin for binding the tensin PTB domain) (Qian
et al., 2007), andDLC1binding to tensin contributes to thegrowth
inhibitory activity of DLC1 (Liao et al., 2007;Qian et al., 2007; Yam
et al., 2006a). Thus, in untransformed cells with DLC and low Src
activity, tensin-3 may tend to be growth inhibitory. It is in this
context that decreased cell migration induced by tensin-3 in the
untransformed MCF10A cell line (Katz et al., 2007) or standard
HEK293 (where tensin-3 did not affect cell proliferation) (Martus-
zewska et al., 2009) may be interpreted. (The HEK293T line used
in the current studies, which is transformed by SV40 large T
antigen, was chosen for our biochemical analyses because it
has higher Src activity.) There could be important differences in
signaling betweenMCF10Aandbreast cancer cell lines, because
we found that EGF treatment of the cancer lines for 24 hr did not
result in a change in the level of tensin-3 (data not shown), in
contrast to the reduction in tensin-3 that began after a few hours
of EGF treatment of MCF10A cells (Katz et al., 2007). As shown
here, Src activity (and perhaps other tyrosine kinases) will help
determine which ligands bind the SH2 domain. It is also likely
that DLC expression, tyrosine phosphorylation of tensin SH2
ligands, and perhaps other factors, may affect ligand binding to
the tensin-3 SH2 domain and whether tensin-3 promotes or
inhibits growth.
The physiologic role of tensin-3 is likely to be complex. In
apparent contrast to MCF10A, colonic crypt epithelial cells
from mice in which tensin-3 has been disrupted migrate more
slowly in vivo than wild-type crypt cells (Chiang et al., 2005).
Consistent with the notion that tensin-3 might regulate normal
growth, tensin-3/ mice display growth retardation and post-
natal lethality, in contrast to mice without functional tensin-1 or
tensin-2 (inactivation of cten has not been reported) (Chiang
et al., 2005; Cho et al., 2006; Lo et al., 1997).
The identification of tensin-3 as a potentially important down-
stream target of Src that in addition binds other Src targets,
such as p130Cas and FAK, could have therapeutic implications.
Src is under active investigation as a therapeutic target because
of its role both in tumor cells and stromal cells (Giaccone and
Zucali, 2008; Johnson and Gallick, 2007). Our data suggest
that some effects resulting from Src inhibition could be attribut-
able, at least in part, to the inhibition of tensin-3. Although Src is
an attractive target in part because it affects multiple signaling
pathways, it is possible that the inhibition of so many pathways
could result in toxicity of normal cells. In such a situation, specif-
ically targeting a Src substrate such as tensin-3 might provide
greater clinical benefit, as, at least in theory, the inhibition of
tensin-3 in normal cells might result in less toxicity than Src
inhibition.256 Cancer Cell 16, 246–258, September 8, 2009 ª2009 Elsevier IncEXPERIMENTAL PROCEDURES
siRNA Transfection
On target plus siRNAs for all four types of human tensins (tensin-1, tensin-2,
tensin-3, and cten), Src, E-cadherin, and for mouse tensin-3, as well as
Risc-free control siRNA, were all from Dharmacon. See Table S1 for target
sequences. Cells were transfected with siRNAs as indicated for 18–24 hr using
lipofectamine 2000 followed by a change of media. Two to three days after
siRNA transfection, cells were counted for setting up various bioassays.
Reduced expression by each siRNA was monitored by immunoblotting with
the appropriate antibody, except for tensin-2, which was analyzed by RT-PCR
because no commercial antibody is available.
MTT, Cell Migration, and Soft Agar Assays
For the MTT colorimetric proliferation/viability assay (Mosmann, 1983), 15,000
cells were seeded in triplicate in 96-well dish and cultured with media contain-
ing 5% FBS for 2–5 days. Cell viability and growth rate were assessed
using the 3-(4-5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Sigma-Aldrich).
Transwell cellmigration assayswereperformedwith 6.5mmdiameter Falcon
cell culture inserts (8 mm pore size; Becton Dickinson) precoated with 0.01%
gelatin, in 24 well cell culture plates. Cells were trypsinized, resuspended in
serum-free media, and transferred to the upper chamber (2.5 3 105 cells in
350 ml); 800 ml media containing 10% FBS was added to the lower chamber.
After incubation for 24 hr, cells remaining on the upper surface of the filter
were removed with a cotton swab; cells that had migrated to the lower surface
were fixed, stained with 1% crystal violet for 10 min, destained, visualized
microscopically, and photographed. The migrated cells were then solubilized
overnight with 1% Triton X-100 (Triton). The collected lysates were quantified
colorimetrically in a spectrophotomer using OD590nm. For soft agar colony
assays, cells (1 3 105 cells) were mixed with complete medium containing
0.4% agar (Difco) and placed over 0.6% of basal agar in 60 mm dishes. Cells
were grown for 2–3 weeks, and colonies were photographed microscopically
and quantified by a colony counter.
Mouse Tumorigenicity Studies
Themouse studies were approved by theNCI Animal Care andUseCommittee
and were conducted in compliance with the approved protocols. H1299 cells
were washed with cold phosphate-buffered saline and diluted in 108/ml with
serum-free medium/Matrigel basement membrane matrix (Becton Dickinson
Labware) at a ratio of 3:1, and injected subcutaneously into NOD/SCID mice
(107 cells per injection). The animals were monitored for tumor growth, and
tumor mass was weighed (in grams) 4 weeks after injection. In addition,
Met-1 and PyMT cells were transfected with Risc-free and mouse tensin-3
siRNA (25 nM smart pool and 25 nM single tensin-3 siRNA 08). Two days after
transfection, cells were injected orthotopically under the fat pad (106 cells per
injection) or in the tail vein (2.5 3 105 cells per injection) in female FVB mice.
Tumor masses in the fat pad were isolated and weighed. Mouse lungs from
tail-vein-injected mice were fixed, subjected to hematoxylin and eosin (H&E)
staining, and the lung metastases were quantified with a microscope.
In Vivo Pull-Down Assay, Coimmunoprecipitation, and
Immunoblotting
Cells were cotransfected with plasmids expressing GST, GST-SH2, or GST-
SH2-PTB proteins and a DLC1 expressing plasmid or control plasmid. In
some experiments, cells were treated for 16 hr with 5 mM HA, 10 mM PP2,
10 mM PI, or 10 mM PD 98059 (all from Calbiochem) prior to cell lysis. Two
days after transfection, cells were lysed with Golden Lysis Buffer (GLB:
20 mM Tris [pH 7.9], 137 mM NaCl, 10% glycerol, 1% Triton, 5 mM EDTA,
1 mM EGTA, 1 mM Na3VO4, 10 mM NaF, 1 mM sodium pyrophosphate,
0.5 mM b-glyceroposphate, and protease inhibitor cocktail tablet [Roche]).
The cleared supernatants were collected, and the amount of protein estimated
by BCA kit (Pierce). Equal amounts of protein from cell extracts were used for
pull-down assays by adding 30 ml glutathione Sepharose-4B slurry (GEHealth-
care) and rotating 3 hr at 4C. The pellets were washed once with GLB, once
with high salt HNTG (20 mM HEPES, 500 mM NaCl, 0.1% Triton-X, 10% glyc-
erol), and twice with low salt of HNTG (20 mM HEPES, 150 mM NaCl, 0.1%
Triton, 10% glycerol), and incubated with Laemmli sample buffer. Fifteen.
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85% for detecting the pull-down proteins, such as DLC1, FAK, p130Cas
(pY410), ILK, Sam68, etc. For coimmunoprecipitation experiments, equal
amounts of protein lysates were incubated with control immunoglobin G
(IgG) or specific antibodies. Thirty microliters of Protein A/G slurry (Pierce)
were added to each immune reaction and rotated overnight at 4C. The immu-
nopellets were washed four times as above. Separation of protein samples
by SDS-PAGE was followed by immunoblotting using specific antibodies
as indicated. For each blot, horseradish peroxidase-conjugated anti-rabbit
or anti-mouse IgG (GE Healthcare) was used for the second reaction at
1:10,000 dilution. Immunocomplexeswere visualized by enhanced chemilumi-
nescence (ECL), using an ECL kit (GE Healthcare).
In Vitro Kinase Assay
Anti-Src immune complexes from various human cell lines or glutathione bead
pull-down pellets from 3T3Src cells, 293T cells, or MDA-MB-468 cells trans-
fected with GST-SH2 variants were washed once with GLB, once with second
buffer (0.5 mM LiCl, 100 mM Tris [pH 7.4]), and once with Src kinase reaction
buffer (100 mM Tris-HCL [pH 7.2], 125 mM MgCl2, 5 mM MnCl2, 2 mM EGTA,
250 mMsodium orthovanadate, 2 mMDTT). In some reactions, 25 ng active re-
combinant kinase (Millipore) was included, as indicated in the figures. Each Src
kinase reaction was carried out in 35 ml reaction buffer containing 1 mM cold
ATP and 2 mCi 32P-gATP at 27C for 20 min. The reaction was stopped by
adding 35 ml 2X Laemmli sample buffer and heating at 95C for 5 min.
SUPPLEMENTAL DATA
Supplementaldata includeSupplementalExperimentalProcedures,onesupple-
mental table, and four supplemental figures and canbe foundwith this article on-
line at http//www.cell.com/cancer-cell/supplemental/S1535-6108(09)00254-2.
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